The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an alert urging women using weight-loss medications like Ozempic, Wegovy, and Mounjaro to employ effective contraception. This recommendation follows reports of 40 pregnancies occurring while patients were using these drugs, raising concerns about their safety during pregnancy. Mounjaro may diminish the effectiveness of some oral contraceptives, prompting a need for barrier contraceptives. The MHRA warns that these medications are not approved for use by pregnant women or by those trying to conceive, due to insufficient safety data.
The Medicines and Healthcare products Regulatory Agency urges women on weight-loss drugs to use effective contraception after 40 pregnancy reports, citing potential risks.
Both Ozempic and Wegovy mimic a hormone to reduce appetite and insulin production, but they are not fully approved for weight loss.”}],
Mounjaro, containing tirzepatide, may reduce the effectiveness of oral contraceptives in overweight individuals, thus necessitating barrier methods like condoms.
The MHRA's alert follows cases where women reported pregnancy while on weight-loss drugs, indicating potential safety concerns regarding the use of these medications.
Collection
[
|
...
]